SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:prod.swepub.kib.ki.se:149527611"
 

Search: onr:"swepub:oai:prod.swepub.kib.ki.se:149527611" > Oxime derivative TF...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Jo, A (author)

Oxime derivative TFOBO promotes cell death by modulating reactive oxygen species and regulating NADPH oxidase activity in myeloid leukemia

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-05-07
  • Springer Science and Business Media LLC,2022

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:149527611
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:149527611URI
  • https://doi.org/10.1038/s41598-022-11543-8DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Several derivatives derived from the oxime structure have been reported as potential anticancer agents in various cancers. Here, we first tested a novel oxime-containing derivative of 2-((2,4,5-trifluorobenzyl)oxy)benzaldehyde oxime (TFOBO) to evaluate its anticancer effect in myeloid leukemic cells. Compared to (2-((2,4,5-trifluorobenzyl)oxy)phenyl)methanol (TFOPM), the oxime derivative TFOBO suppresses leukemic cell growth by significantly increasing reactive oxygen species (ROS) levels and cell death. Leukemic cells treated with TFOBO displayed apoptotic cell death, as indicated by nuclear condensation, DNA fragmentation, and annexin V staining. TFOBO increases Bax/Bcl2 levels, caspase9, and caspase3/7 activity and decreases mitochondrial membrane potential. ROS production was reduced by N-acetyl-l-cysteine, a ROS scavenger, diphenyleneiodonium chloride, a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor, after exogenous TFOBO treatment. ROS inhibitors protect leukemic cells from TFOBO-induced cell death. Thus, our study findings suggest that TFOBO promotes apoptosis by modulating ROS and regulating NADPH oxidase activity. Collectively, the oxime-containing derivative TFOBO is a novel therapeutic drug for myeloid leukemia.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kwak, JH (author)
  • Woo, SY (author)
  • Kim, BY (author)
  • Son, Y (author)
  • Choi, HS (author)
  • Kim, J (author)
  • Kwon, M (author)
  • Cho, HR (author)
  • Eo, SK (author)
  • Nam, JH (author)
  • Kim, HS (author)
  • Baryawno, NKarolinska Institutet (author)
  • Lee, D (author)
  • Kim, K (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Scientific reports: Springer Science and Business Media LLC12:1, s. 7519-2045-2322

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view